WE’RE WORKING TO SECURE

THE HEALTH OF OUR NATION

AND THE SECURITY OF OUR

NATION’S DRUG SUPPLY

LEARN HOW

SALUBRENT NOW OFFERS STATE-OF-THE-ART ANALYTICAL TESTING SERVICES

Salubrent has officially launched the first of many planned state-of-the-art analytical labs, which will be strategically located around the country to flexibly address the changing needs of today’s pharmaceutical and biotech companies. With an emphasis on quality, innovation, and responsiveness, our scientific team will provide the testing stability studies, and analytical methods required for the successful development of the next generation of therapeutics.

AND SOON WE’LL BE OFFERING FLEXIBLE, ASEPTIC FILL & FINISH FORMULATION AND MANUFACTURING

Beginning in 2024, Salubrent will launch a new technology-focused contract development and manufacturing organization (CDMO) dedicated to flexible, state-of-the-art aseptic fill & finish solutions. As a full-service CDMO, Salubrent will focus on serving clinical and commercial stage pharmaceutical and biotech companies in need of flexible batch production of sterile injectable products using the latest in fill-finish technologies.

We have created a company focused on the Salubrent Customer Experience by meeting, and exceeding, our customers’ project objectives.

Terry NovakPresident & CEO, Salubrent Pharma Solutions

We are a technology-enabled CDMO offering comprehensive analytical services to pharma and biotech companies. Salubrent also has the quality and regulatory expertise to successfully bring your product to the clinic, and beyond.

ANALYTICAL
SERVICES

We are now offering comprehensive analytical services, staffed with experience scientists who will use a flexible approach to meet your specific analytical needs. We will work closely with you to develop and maintain unique methodologies to optimize the stability and effectiveness of your drug candidate from scale-up to commercial manufacturing.
LEARN MORE »

FORMULATION
DEVELOPMENT

(BEGINNING IN 2022)
Whether small or large molecule, Salubrent offers flexible solutions for your small commercial batch needs, moving you through the development process quickly and efficiently without the need of a reiterative validation process. And through our US-based API partnerships, we can ensure the security of your supply.
LEARN MORE »

MANUFACTURING
SERVICES

(BEGINNING IN 2024)
We expect our fill & finish services to be operational during 2024 at our state-of-the-art purpose-built facility using innovative robotic manufacturing technologies that will provide flexible drug delivery solutions in formats including single-use consumables and ready-to-use, pre-sterilized containers and closures.
LEARN MORE »

QUALITY &
REGULATORY SERVICES

Staffed with experienced quality and compliance experts, our team will oversee every step of the development and manufacturing process to deliver consistent quality for the security of your drug supply.

We delight our customers with excellent customer service, leading-edge technologies, and our deep knowledge of aseptic fill & finish solutions. Reach out and learn more.

Latest News

Press Release
February 28, 2022

Bill Conway Joins Salubrent as Sr. Director of Business Development

KANNAPOLIS, N.C., Feb. 28, 2022 - Salubrent announces the addition of Bill Conway to its Management Team as Senior Director of Business Development. Conway brings more than 30 years of experience with a broad range of experience with both large…
Salubrent News
January 18, 2022

Salubrent: GCHS & GC/MS Capabilities Handle Complex Projects

Special Feature from the annual Drug Development & Delivery report: Analytical Testing Trends in 2022 “Salubrent Pharma Solutions is a recently formed CDMO focused on supporting the shift toward biologics and personalized medicines, where small batch fill and finish services,…
Press Release
January 6, 2022

Harish Dave, MB, ChB, MBA, Joins Salubrent Board

KANNAPOLIS, N.C., Jan. 6, 2022-- Salubrent announces the addition of Dr. Harish Dave to its Board of Directors. Dr. Dave brings more than 35 years of experience in the sciences, academia, finance and pharma industry, including extensive work with the…

Enough About Us.

Tell Us About Your Next Project.